Help governments and healthcare organisations to spend their budgets wisely

What is this track?
Meet the case of Charlie

With limited treatment options remaining, Charlie’s estimated 10-year survival rate is only 32%. Fortunately, a groundbreaking therapy recently approved by the European Medicines Agency offers the potential to cure Charlie. However, this therapy is associated with high costs and therefore it is important to evaluate whether the benefits outweigh the costs.

The European Union (EU) aims for universality, solidarity, access to quality healthcare, and equity for all its citizens. This means that no one should be denied access to quality care, and services should be available based on patients’ needs.

Do you wonder if:

• How should we evaluate (long term) benefits of Charlie’s treatment?
• What type of costs should be included in the evaluation of Charlie’s treatment?
• How much should we be willing to pay for Charlie’s treatment, considering the benefits?
• What information is required for a reimbursement decision for Charlie’s treatment

Can you help?

Are you passionate about making a positive impact on healthcare decision-making? Are you interested in addressing the ethical and economic dilemmas surrounding healthcare interventions? If so, this track is for you!

Enjoy the best of Rotterdam and Oslo

This track is a partnership between the Erasmus University Rotterdam (2nd semester) and the University of Oslo (3rd semester). They excel in the fields of health economics, healthcare management and health policy. You will enjoy top academic education in two trendy, multicultural European cities. Both with thriving healthcare sectors and high-quality living standards.